Invaio Sciences secures $ 50 million debt financing to develop and commercialize agricultural solutions to fight climate change



CAMBRIDGE, Mass., October 13, 2021 / PRNewswire / – Invaio Sciences, Inc., a leading pioneering company that unleashes the potential of natural systems to accelerate the transition to sustainable agriculture to urgently combat climate change, concluded a $ 50 million loan and guarantee agreement with K2 HealthVentures (K2HV), an investment company focused on health care and life sciences.

The funds will be used to accelerate the research, development and commercialization of Invaio platforms that focus on the discovery of natural active ingredients, the development of unique precision delivery systems and the understanding of new modes of action. . Invaio’s pioneering solutions have the potential to reduce the use of pesticides and chemical fertilizers, conserve more water, and improve the efficiency of the agricultural food system to benefit consumers and the planet.

“Invaio’s partnership with K2HV will help us expand our geographic footprint and accelerate the development of revolutionary platforms focused on the development of integrated solutions in three market segments: perennials, row crops and market gardening”, said Ignatius Martinez, co-founder and CEO of Invaio and general partner of Flagship Pioneering. “Our ambition is to create the most efficient and valuable crop health business on the planet. The world is changing rapidly and food production practices must adapt to keep up with changing consumer demands, changing environmental conditions and increased stress on ecological resources. ”

“Fortunately, over the past two decades, the management of human disease has increasingly made use of safer and more effective precision medicine techniques. The agricultural world has not shifted to this paradigm and still suffers from inefficient management of pests and diseases and negative consequences for the environment. We believe Invaio’s platform technology suite is the precision medicine solution for the world of agriculture, ”said Parag Shah, founding CEO and CEO of K2 HealthVentures. “This funding follows our strategy of partnering with pioneering life science technology companies with world-class leadership that aim to provide solutions to critical global challenges. “

About Invaio
Invaio Sciences, Inc., a pioneering flagship company, has focused on unleashing the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address the challenges of climate change. Founded by Flagship Pioneering in 2018, Invaio leverages discoveries from various fields including human therapeutics, agriculture, environmental science and advanced manufacturing. For more information, please visit or follow us on Twitter Where LinkedIn.

About Flagship Pioneering:
Flagship Pioneering designs, creates, resources and develops premier bioplatform companies to transform human health and sustainability. Since its launch in 2000, the company, through its Flagship Labs unit, has applied its unique hypothesis-based innovation process to create and nurture over 100 science-based companies, which has generated an aggregate value of over $ 212 billion. To date, Flagship has deployed over $ 2.5 billion in capital for the creation and growth of its pioneering businesses, as well as over $ 19 billion in follow-on investments from other institutions. The current flagship ecosystem includes 42 transformative companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB) and Sigilon Therapeutics (NASDAQ: SGTX).

About K2 HealthVentures
K2 HealthVentures is an alternative investment company focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and health sectors. The investment team includes collaborative and experienced professionals with diverse backgrounds in finance and operations, as well as in-depth domain knowledge in various healthcare sectors. A unique permanent and flexible capital structure enables the company to provide creative and adaptive financing solutions and to meet the changing capital needs of its portfolio companies as they grow. K2HV is driven by the dual purpose of profit and purpose – aiming to fuel the growth of innovative businesses that will ultimately improve the lives of patients and to return a percentage of the profits from the investment to underserved areas of care. health.

SOURCE Invaio Sciences

Related links

Source link


About Author

Comments are closed.